Lanreotide Acetate

Cipla USA, Inc. has initiated a Class II nationwide recall of multiple lots of Lanreotide Injection, 120 mg/0.5 mL, due to a lack of sterility assurance. This critical regulatory action stems from FDA observations at its contract manufacturer, Pharmathen International, S.A., highlighting deficiencies in visual inspection procedures. This impacts supply and demands immediate attention from procurement and regulatory teams.

Cipla USA, Inc. has initiated a Class II nationwide recall for 15,221 syringes of Lanreotide Acetate Injection due to particulate matter. This event, identified on January 2, 2026, signals critical quality control vulnerabilities impacting patient safety and supply chain integrity for this vital somatostatin analog. Procurement and regulatory teams must assess immediate supply risks and review internal quality assurance protocols.